Fidelity SPDR Advertisement
Home > Boards > US OTC > Miscellaneous >

EP Global Communications, Inc. (EPGL)

Add EPGL Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator flaflyersfan, Doubledown22, Stock Barber, Valiant, Badali, itsmebroke
Search This Board:
Last Post: 9/2/2014 2:35:34 AM - Followers: 377 - Board type: Free - Posts Today: 60

(This "Intro Box" is NOT maintained byEPGL Medical Sciences and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on EPGL Medical Sciences,  go to company website


Company Summary

EP Global Communications, Inc.  ( EPGL) / EPGL Medical Sciences, Inc. is a new biomedical device manufacturing and marketing company.  The Company is currently working to invent and develop additional cutting edge medical device technology products to introduce subsequently to the MPDD, including biomedical devices which utilize Bio-Micro-Electro Mechanical Systems technology (Bio-MEMS). Bio-MEMS is one of the fastest growing and promising new frontiers in medical technology today with possibilities in both medical diagnostic and treatment applications. EP Global Communications, Inc. is an advanced technology development company for both medical devices and consumer electronics.  EPGL also holds an FDA 510k cleared medical device called the MPD1. The MPD1 is a revolutionary new diagnostic and therapeutic tool for the muscular originated pain in the human body.


In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. The Development Agreement was signed the week of December 8, 2013. The two companies have signed a confidentiality agreement due to the sensitive and competitive nature of the technology.  Details of the first Development Agreement will remain confidential for now.  However, PwC as custodian for AJW Funds Board membership of EPGL has been apprised of the Agreement and its details.


EPGL Medical Science's Competitive Edge

As of July 27, 2012, EP Global Communications, Inc. (EPGL) has successfully been restructured by Pricewaterhouse Coopers (PwC), which is the world's largest financial accounting firm.   PwC, along with all other major debt holders, have converted 100% of the Company's debt to equity, estimated to be $10 million USD, becoming major equity partners in the Company.  Via the restructuring and as previously announced in public statements, EPGL will now move ahead with plans to enter the growing medical device industry.  EPGLD, through acquisition, now holds rights to at least one FDA 510k cleared medical device and is currently working on bringinf new technolgies to market.EPGL Medical Sciences, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.  The combined national and international market for the MPDD device is estimated at $4.5 billion dollars annually in device sales and recurrent education and training revenues.




 Brady Peterson - IR/PR Manager

Brady Peterson was recently named Manager of Investor Relations and Public Relations as well as Information Technologies for EPGL Med. Mr. Peterson is the consummate professional who brings 15 years of Customer Relations and marketing experience to EPGL. The EPGL team is pleased to have him aboard and we believe customers and investors alike will appreciate his professionalism.



David T. Markus Ph.D  - Company Vice President - BioMems Development

David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery.


Eric Lee M.D.M.A.

Eric Lee M.D. M.A. graduated from Yale University and completed medical school at Boston University. He completed his residency in Physical Medicine and Rehabilitation at NYU Langone Medical Center where he has continued with a Pain Medicine fellowship. Dr. Lee is intimately familiar with the MPDD device and used it as a diagnostic tool in a study of using advanced techniques to treat myofascial pain along with Dr. Michel Dubois MD at NYU. Dr. Lee's professional interests include pain diagnosis and treatment, disorders of the spine, central, and peripheral nervous system, with a special interest in advanced interventional techniques and minimally invasive spinal procedures. Dr. Lee will oversee further additions to the EPGL Medical management team and advancement of new medical devices technologies the Company has interest in pursuing.


Ryan M. Stellar M.E. B.E.

EPGL is proud to have Ryan M. Stellar M.E. B.E. as part of the team. Mr. Stellar is a highly accomplished biomedical engineer who was intimately involved with the creation of the MPDD device as the Chief Engineer during its creation at Stevens Proof of Concept (SPOC). Mr. Stellar graduated from Stevens Institute of Technology in 2006 with a degree in Biomedical Engineering and a Minor in Economics. Mr. Stellar has been with Medtronic, Inc. for six years prior to leaving this year. While at Medtronic, among many other accomplishments, he successfully directed global launches of two portfolio critical products in the cardiac rhythm device market: DF4 Lead Connector System & CareLink Network for Heart Failure. Mr. Stellar is an expert in medical device manufacturing resources and distribution channels as well as customer relationship management.


Reid H. Erickson - Financial Partnership Strategy Advisor

Reid H. Erickson is Financial Partnership Strategy Advisor and candidate for Board of Directors. Reid is Founder, Chairman and CEO, Beneri International Corporation. He is an innovative, visionary leader spearheading green technology commercialization and the growth of sustainable businesses. With nearly three decades in the green and sustainable industry, Reid has assisted numerous early stage companies as an investor, advisor, consultant, board member or executive manager providing leadership and access to his worldwide network of entrepreneurial specialists dedicated to sustainable development.


Michael Hayes - Interim Company President & CEO

Michael Hayes was President of Digital Health Sciences, Inc. prior to that Company being acquired by EPGL in July 2012. Mr. Hayes has presided over the debt restructuring of EP Global Communications, Inc. along with Pricewaterhouse Coopers since early 2012. Mr. Hayes is now in charge of assembling a new management team for EPGL, including all Company management, medical and scientific personnel going forward. Mr. Hayes has made it a singular priority to bring aboard only the world’s top professionals in the field of medical sciences to EPGL and thereby build the Company into a major player in the medical device industry over the next several years. Mr. Hayes has also committed to prioritizing shareholders and creating significant value for their investments over time.


Noah T. Kaufman, M.D. - Vice President of Emergency Medicine Innovations

Noah T. Kaufman, M.D. as Vice President of Emergency Medicine Innovations and candidate for Board of Directors. Dr. Kaufman will add valuable energy and insight from the perspective of emergency medicine, which is a significant market for EPGL moving into the future. He is a highly accomplished physician in his field. As Director of Clinical Emergency Ultrasound, Dr. Kaufman is in the top ranks for patient scores and outcomes. Dr. Kaufman is also currently the attending Emergency Physician for Barton Memorial Hospital ER and the Carson Valley Medical Center ER at South Lake Tahoe, California. His education includes Akron General Medical Center, Akron, OH - EM Residency 2006. Tulane University School of Medicine, New Orleans, LA - MD 2003, and University of Miami, Coral Gables, FL - BS 1996


Andereas Markus  - International Distributor

International Innovations is EPGL Medical Sciences exclusive new arm for marketing and distribution globally. Mr. Andereas Markus (M.B.A & M.Sc Eng) has both a strong Business and Engineering educational background. He is a talented and extremely well connected marketeer whose ability has helped him develop more than 20 years of experience in international marketing, engineering and distribution. This includes various high end products distributed to all of Asia, America, Europe, the Middle East and Africa. His professional experience has seen him working with all of the top 20 economic markets in the world.


As the new leader of International distribution for EPGL Medical Sciences, Andereas and his staff will treat physicians to a higher "VIP standard" of service, by listening carefully to what the doctor needs in medical device products, training and technical support. Andereas will implement EPGL's new and innovative approach to medical device marketing globally. This includes the willingness to make himself and EPGL staff available virtually 24/7 to service health care professionals and organizations in a timely manner. He will implement EPGL's new concierge style service to the world's top clients in health care from CEO's of international hospitals to front-line physicians and all between. This exceptional service and marketing model will ensure that health care professionals will have the best experience possible with EPGL Medical and its products. It is for these simple but powerful reasons that EPGL Medical Sciences will build a strong and loyal clientele worldwide for its new medical devices.



EPGL Medical Science's Latest Developments

EPGL Medical Science's will be among the first Medical Device Makers to Implement Google Glass technology and the API Mirror platform for use with its medical devices. EPGL has several new devices in development which are being developed with the latest smart platforms in mind. "Physicians using our devices will be able to utilize technology such as Google Glass while performing procedures, using our devices and viewing feedback data in real-time.  In addition to integrating smart technology such as Google Glass, EPGL Medical now has a "secret weapon" medical device technology advancement which no other medical device company has. This single technology will be the catalyst for dozens of new medical device technologies to be produced or licensed by the Company. The Company is in the process of filing more than 50 patents to protect this unique and valuable innovation.

In addition to the new technologies EPGL is progressing, the Company is implementing an innovative new approach to medical device marketing with a business model which guarantees residual income from each new device sold. The Company's VIP approach to its physician customers with on-going technical support and educational training, will build strong loyalty to our medical devices.  EPGL  will reveal its new BioMEMS medical device platform, code named "TopSpin", during a series of conference calls hosted by David T. Markus Ph.D. this week. The calls will take place seven consecutive nights this week, starting Wednesday April 24 and concluding Tuesday April 30, 2013. As one of the top BioMEMS engineers in the world, Dr. Markus along with others, will unveil the importance and value of EPGL's new BioMEMS device platform in today's medical marketplace. The new technology stands to spawn potentially dozens of new medical devices, giving doctors innovative new tools for diagnosis and treatment.

About EPGL Medical Science's Share Structure

EPGL has a share structure of 5 billion authorised shares with approximately 4.5 billion shares restricted and a float of approximately 499 million.  Following a very sucessfull Reverse Split EPGL has decreased the float by 90% and increased share holder value by over 500% since The company has strongly stated many times that they will not sell shares into the retail market.  They are here to build a real company and impliment real growth. Since restructuring EPGL has not increased the Float/OS/AS and have given us there word on countless occasions they will not do so.

SEC Filings
Share Structure
EPGL On Twitter
About the MPDD
EPGL Management Team
Contact EPGL Medical Sciences or, Phone: 877-287-6175

EPGL Medical Science's Press Release Highlights

1.  10:1 Reverse split to be voted upon by shareholders                                                                    
2. All major debt holders have agreed to convert 100% of the company's debt to equity 
3. Authorized shares will remain at the present level with no increase in shares
4. Exlusive rights to a medical device with FDA 510k clearance for marketing
5. New equity partners involved via merger
6. The acquisition will be in exchange for equity in the company resulting in no new debt to company
7. Current EPGL management will resign
8. New management with broad experience in the medical device industry will be assigned in coming weeks
9. Top Physicians and Scientists will be part of the new management
10. Proxy materials are being prepared and details will be mailed to shareholders about meeting in coming days
11. Reached a restructuring agreement with the liquidator of AJW funds to convert 100% of the Company's debt into equity
12. Restructure the Company into a medical device manufacturer
13. The Company will be given exclusive rights to a promising new medical device which has successfully achieved FDA 510k clearance in the pain diagnosis and management arena
14.   The Company plans to market the device to physicians, allied health care professionals and rehabilitation specialists worldwide
15. The potential market for this unique medical device is estimated to exceed $4.5 billion dollars annually
16. Current Company management will resign amicably
17. New management with broad experience in the medical device industry will be assigned, including top researchers, physicians and scientists
18. The Company name will change to EP Global Health Sciences, Inc.
19. Will retain the EPGL ticker symbol
20. The Company believes this restructuring agreement is an extremely positive development and will offer shareholders and investors the opportunity for a significant potential return on investment
21. Shareholders will be asked to approve a proposed reverse split of the Company's common stock so as to provide sufficient common shares for increased trading value and to raise funding necessary to implement the marketing plans and programs necessary for successful implementation of the new medical device business

EPGL Chart



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
EPGL News: EPGL Fielding Major Consumer Electronics Partnerships 08/29/2014 01:52:00 PM
EPGL News: PwC To Hold EPGL Equity 04/14/2014 01:42:00 PM
#61071  Sticky Note Breakdown of CooperVision & EPGL Agreement: Valiant 09/01/14 10:08:11 AM
#61064  Sticky Note EPGL Fielding Major Consumer Electronics Partnerships Badali 08/31/14 10:59:57 PM
#60717  Sticky Note jhnvtjll 08/29/14 06:21:56 PM
#55291  Sticky Note The possibilities of $EPGL exploding in value are Doubledown22 07/22/14 07:26:43 PM
#55008  Sticky Note New Investor Q&A H8ster 07/21/14 04:20:33 AM
#61283   Just read over the conversations from tonight've davidr2448 09/02/14 02:35:34 AM
#61282   That is very plausible. What it comes Valiant 09/02/14 02:17:02 AM
#61281   I think it is possible that some partners YogInvest 09/02/14 02:12:32 AM
#61278   But proof? But numbers? But....come one. Valiant 09/02/14 01:54:09 AM
#61277   Agreed, but I think smart contact lenses are Valiant 09/02/14 01:52:19 AM
#61276   Not every company PR's such deals... and they Stock Barber 09/02/14 01:52:02 AM
#61275   Current market size for contact lenses is totally YogInvest 09/02/14 01:48:59 AM
#61274   It's not just cool ideas. You don't Valiant 09/02/14 01:46:32 AM
#61273   I am still waiting for those similar deals! Valiant 09/02/14 01:43:41 AM
#61272   There is no other explanation. Stock Barber 09/02/14 01:43:30 AM
#61271   Simple math. If I show up to Valiant 09/02/14 01:38:30 AM
#61270   If EPGL had technology worth greater than their Stock Barber 09/02/14 01:34:39 AM
#61269   Exactly!! EPGL vikingzskillz 09/02/14 01:28:42 AM
#61268   Me either. This is why companies buy Valiant 09/02/14 01:28:12 AM
#61267   There isn't , I have not seen vikingzskillz 09/02/14 01:26:10 AM
#61265   Exactly...let's compare these deals apples to apples. Valiant 09/02/14 01:24:02 AM
#61264   Lol, I want to know the IP too! vikingzskillz 09/02/14 01:22:55 AM
#61263   Name the deals? I want to see Valiant 09/02/14 01:22:06 AM
#61262   I don't care what deal you been apart vikingzskillz 09/02/14 01:21:39 AM
#61261   In every deal that I have been part Stock Barber 09/02/14 01:20:10 AM
#61260   Haha! They will find out shortly. Valiant 09/02/14 01:19:55 AM
#61259   The point is being missed here. The Valiant 09/02/14 01:18:03 AM
#61258   They released the financial benefits: Valiant 09/02/14 01:15:14 AM
#61257   I know, it's undervalued soon it justifies vikingzskillz 09/02/14 01:14:29 AM
#61256   Google, Novartis, and CooperVision reached out to EPGL Stock Barber 09/02/14 01:12:56 AM
#61255   Exactly lol, and some say this isn't an vikingzskillz 09/02/14 01:12:29 AM
#61254   Exactly. Why do you think they took Valiant 09/02/14 01:10:31 AM
#61253   COO thought they get zero while spending millions vikingzskillz 09/02/14 01:08:13 AM
#61252   this deal is exceptional for EPGL shareholders Stock Barber 09/02/14 01:06:39 AM
#61251   Lmfao...This agreement is very lucrative for EPGL shareholders, vikingzskillz 09/02/14 01:06:34 AM
#61250   Very well could be! Here is the Valiant 09/02/14 01:05:48 AM
#61249   Actually I believe EPGL choose Cooper over vikingzskillz 09/02/14 12:59:41 AM
#61248   Two reasons I can think of immediately are: Valiant 09/02/14 12:58:39 AM
#61247   Agreed. Mrzach3590 09/02/14 12:56:57 AM
#61246   So you saying they made a deal with vikingzskillz 09/02/14 12:56:41 AM
#61245   Lol, guess what , this one deal alone vikingzskillz 09/02/14 12:55:36 AM
#61244   The whole reason Cooper locked them up is Stock Barber 09/02/14 12:54:23 AM
#61243   SB had a buddy of his invested here, Afghanistuck 09/02/14 12:54:02 AM
#61242   This is exactly my point. Mrzach3590 09/02/14 12:51:13 AM
#61241   Exactly!!! That is the beauty of it. Valiant 09/02/14 12:50:34 AM
#61240   So we have another 7000% PPS increase coming? vikingzskillz 09/02/14 12:49:31 AM
#61239   There is the company, and there is the Stock Barber 09/02/14 12:47:56 AM
#61238   Where you hear that rumor ? Lol nowy257 09/02/14 12:47:32 AM
#61237   Lol, well said ->EPGL going parabolic soon! vikingzskillz 09/02/14 12:46:41 AM
#61236   No SB you correct. You have stated Afghanistuck 09/02/14 12:45:47 AM
#61235   It is obvious to me that EPGL's I.P. Stock Barber 09/02/14 12:43:25 AM
#61234   Yes, next week. Mrzach3590 09/02/14 12:42:54 AM
#61233   It is obvious to me that EPGL's I.P. paidbasher123 09/02/14 12:40:07 AM
#61231   Really? How is my opinion far from reality? Stock Barber 09/02/14 12:38:35 AM
#61229   This is only your opinion sir and is nowy257 09/02/14 12:35:06 AM